You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethadone
Accession NumberDB00333  (APRD00485)
TypeSmall Molecule
GroupsApproved
DescriptionA synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). In Australia methadone is a Schedule 8 (controlled) drug.
Structure
Thumb
Synonyms
(+-)-Methadone
(+/-)-Methadone
(±)-methadone
6-Dimethylamino-4,4-diphenyl-3-heptanone
dl-Methadone
Methadonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Disketstablet40 mg/1oralRoxane Laboratories, Inc1973-03-14Not applicableUs
Dolophinetablet5 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Dolophinetablet10 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Dolophine Hydrochloridetablet5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Dolophine Hydrochloridetablet10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-01-01Not applicableUs
Metadoltablet5 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadoltablet10 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadolsolution1 mgoralPaladin Labs Inc2003-07-11Not applicableCanada
Metadoltablet25 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadolliquid10 mgoralPaladin Labs Inc2000-05-05Not applicableCanada
Metadoltablet1 mgoralPaladin Labs Inc2003-07-29Not applicableCanada
Metadol-Dtablet25 mgoralPaladin Labs IncNot applicableNot applicableCanada
Metadol-Dsolution1 mgoralPaladin Labs Inc2014-08-18Not applicableCanada
Metadol-Dtablet1 mgoralPaladin Labs IncNot applicableNot applicableCanada
Metadol-Dtablet5 mgoralPaladin Labs IncNot applicableNot applicableCanada
Metadol-Dliquid10 mgoralPaladin Labs Inc2001-08-03Not applicableCanada
Metadol-Dtablet10 mgoralPaladin Labs IncNot applicableNot applicableCanada
Methadone Hydrochloridetablet10 mg/1oralDIRECT RX2014-01-01Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC1947-08-13Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadone Hydrochloridepowder1 g/goralMallinckrodt, Inc.2012-04-30Not applicableUs
Methadone Hydrochlorideinjection, solution10 mg/mLintramuscular; intravenous; subcutaneousMylan Institutional LLC1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralSTAT Rx USA LLC1947-08-13Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralRoxane Laboratories, Inc1947-08-13Not applicableUs
Methadoseconcentrate10 mg/mLoralMallinckrodt, Inc.2010-03-10Not applicableUs
Methadosesolution10 mgoralMallinckrodt Canada Ulc2013-01-03Not applicableCanada
Methadoseconcentrate10 mg/mLoralAtlantic Biologicals Corps2010-03-10Not applicableUs
Methadoseconcentrate10 mg/mLoralUnit Dose Services2010-03-10Not applicableUs
Methadosesolution10 mgoralMallinckrodt Canada Ulc2013-01-03Not applicableCanada
Methadose Sugar-freeconcentrate10 mg/mLoralMallinckrodt, Inc.2010-03-10Not applicableUs
PMS-methadonetablet25 mgoralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadonetablet1 mgoralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadonetablet5 mgoralPaladin Labs IncNot applicableNot applicableCanada
PMS-methadonetablet10 mgoralPaladin Labs IncNot applicableNot applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methadone Hydrochloridetablet5 mg/1oralbryant ranch prepack2009-05-19Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralMallinckrodt, Inc.2009-05-19Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralAscend Laboratories, LLC2012-01-16Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-10-11Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralRoxane Laboratories, Inc1988-04-30Not applicableUs
Methadone Hydrochloridesolution5 mg/5mLoralVista Pharm Inc2010-08-01Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralAurolife Pharma, LLC2015-09-15Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralPhysicians Total Care, Inc.2004-01-07Not applicableUs
Methadone Hydrochloridesolution10 mg/5mLoralRoxane Laboratories, Inc.1982-08-30Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-01-16Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralMallinckrodt, Inc.2009-05-19Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralAmerican Health Packaging2014-10-02Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-09-15Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralRoxane Laboratories, Inc1988-04-30Not applicableUs
Methadone Hydrochloridesolution5 mg/5mLoralAtlantic Biologicals Corps1981-05-22Not applicableUs
Methadone Hydrochloridesolution10 mg/5mLoralVista Pharm Inc2010-08-01Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralPhysicians Total Care, Inc.2007-03-12Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralVista Pharm Inc2009-10-30Not applicableUs
Methadone Hydrochloridetablet40 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralH.J. Harkins Company Inc.2009-05-19Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralRoxane Laboratories, Inc1988-09-06Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralVista Pharm, Inc.1998-05-29Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralSTAT Rx USA LLC2009-05-19Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralbryant ranch prepack2009-05-19Not applicableUs
Methadone Hydrochloridetablet40 mg/1oralMallinckrodt, Inc.2010-08-31Not applicableUs
Methadone Hydrochlorideconcentrate10 mg/mLoralVista Pharm Inc2011-12-01Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralAurolife Pharma, LLC2015-09-15Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralMajor Pharmaceuticals2012-01-16Not applicableUs
Methadone Hydrochloridetablet5 mg/1oralH.J. Harkins Company Inc.2009-05-19Not applicableUs
Methadone Hydrochloridesolution5 mg/5mLoralRoxane Laboratories, Inc.1981-05-22Not applicableUs
Methadone Hydrochloridetablet40 mg/1oralVista Pharm, Inc.1998-03-25Not applicableUs
Methadone Hydrochloridetablet10 mg/1oralSTAT Rx USA LLC2009-05-19Not applicableUs
Methadosetablet5 mg/1oralMallinckrodt, Inc.2010-02-23Not applicableUs
Methadose Dispersibletablet40 mg/1oralMallinckrodt, Inc.2010-08-31Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AdolanNot Available
DepridolNot Available
HeptadonNot Available
HeptanonNot Available
KetalginNot Available
MephenonNot Available
PhyseptoneNot Available
PolamidonNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methadone Hydrochloride
1095-90-5
Thumb
  • InChI Key: FJQXCDYVZAHXNS-UHFFFAOYNA-N
  • Monoisotopic Mass: 345.18594223
  • Average Mass: 345.906
DBSALT000346
Categories
UNIIUC6VBE7V1Z
CAS number76-99-3
WeightAverage: 309.4452
Monoisotopic: 309.209264491
Chemical FormulaC21H27NO
InChI KeyInChIKey=USSIQXCVUWKGNF-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
IUPAC Name
6-(dimethylamino)-4,4-diphenylheptan-3-one
SMILES
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassDiphenylmethanes
Direct ParentDiphenylmethanes
Alternative Parents
Substituents
  • Diphenylmethane
  • Phenylpropylamine
  • Aralkylamine
  • Gamma-aminoketone
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.
PharmacodynamicsMethadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.
Mechanism of actionMethadone is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.
Related Articles
AbsorptionWell absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.
Volume of distribution
  • 1.0 to 8.0 L/kg
Protein bindingIn plasma, methadone is predominantly bound to α1-acid glycoprotein (85% to 90%).
Metabolism

Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine.

SubstrateEnzymesProduct
Methadone
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)Details
2-Ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium (EDDP)
2-Ethyl-5-methyl-3,3-diphenyl-1-pyrroline (EMDP)Details
Route of eliminationThe elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion. Unmetabolized methadone and its metabolites are excreted in urine to a variable degree.
Half life24-36 hours
Clearance
  • 1.4 to 126 L/h
ToxicityIn severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Methadone Metabolism PathwayDrug metabolismSMP00624
Methadone Action PathwayDrug actionSMP00408
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9772
Caco-2 permeable+0.7841
P-glycoprotein substrateSubstrate0.6224
P-glycoprotein inhibitor IInhibitor0.7627
P-glycoprotein inhibitor IINon-inhibitor0.9101
Renal organic cation transporterNon-inhibitor0.5851
CYP450 2C9 substrateNon-substrate0.7822
CYP450 2D6 substrateNon-substrate0.7743
CYP450 3A4 substrateSubstrate0.66
CYP450 1A2 substrateInhibitor0.5312
CYP450 2C9 inhibitorNon-inhibitor0.864
CYP450 2D6 inhibitorInhibitor0.5449
CYP450 2C19 inhibitorNon-inhibitor0.8177
CYP450 3A4 inhibitorNon-inhibitor0.5507
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6586
Ames testNon AMES toxic0.946
CarcinogenicityCarcinogens 0.6315
BiodegradationNot ready biodegradable0.9888
Rat acute toxicity3.5250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.947
hERG inhibition (predictor II)Inhibitor0.7606
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roxane laboratories inc
  • Vistapharm inc
  • Mallinckrodt chemical inc
  • Bioniche pharma usa llc
  • Sandoz inc
  • Mallinckrodt inc
  • The pharmanetwork llc
Packagers
Dosage forms
FormRouteStrength
Tabletoral40 mg/1
Tabletoral10 mg/1
Tabletoral5 mg/1
Liquidoral10 mg
Tabletoral1 mg
Tabletoral10 mg
Tabletoral25 mg
Tabletoral5 mg
Solutionoral1 mg
Concentrateoral10 mg/mL
Injection, solutionintramuscular; intravenous; subcutaneous10 mg/mL
Powderoral1 g/g
Solutionoral10 mg/5mL
Solutionoral5 mg/5mL
Solutionoral10 mg
Prices
Unit descriptionCostUnit
Methadone hcl 10 mg/ml vial7.48USD ml
Methadone hcl powder5.91USD g
Metadol 25 mg Tablet1.69USD tablet
Metadol 10 mg Tablet0.9USD tablet
Methadone intensol 10 mg/ml0.85USD ml
Metadol 5 mg Tablet0.56USD tablet
Methadone hcl 10 mg tablet0.37USD tablet
Metadol Concentrate 10 mg/ml Liquid0.37USD ml
Methadone hcl 5 mg tablet0.34USD tablet
Dolophine hcl 10 mg tablet0.21USD tablet
Metadol 1 mg Tablet0.17USD tablet
Methadose 5 mg tablet0.16USD tablet
Methadose 10 mg tablet0.14USD tablet
Dolophine hcl 5 mg tablet0.13USD tablet
Metadol 1 mg/ml Solution0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point235.0 °CNot Available
logP3.93HANSCH,C ET AL. (1995)
pKa8.94 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.0059 mg/mLALOGPS
logP4.14ALOGPS
logP5.01ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)18.78ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.27 m3·mol-1ChemAxon
Polarizability36.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-00di-9210000000-7542d8c3f742c7713c13View in MoNA
References
Synthesis Reference

Charles J. Barnett, “Modification of methadone synthesis process step.” U.S. Patent US4048211, issued August, 1952.

US4048211
General References
  1. Kell MJ: Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addict Dis. 1994;13(1):5-26. [PubMed:8018740 ]
  2. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. [PubMed:12405865 ]
  3. Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000 Oct-Nov;67(5-6):347-64. [PubMed:11064485 ]
  4. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. [PubMed:17313907 ]
  5. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL: Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005 Oct;100(10):1496-509. [PubMed:16185211 ]
External Links
ATC CodesN07BC02N02AC52
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelDownload (327 KB)
MSDSDownload (60 KB)
Interactions
Drug Interactions
Drug
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Methadone.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Methadone.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Methadone.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methadone is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE is combined with Methadone.
AbacavirThe therapeutic efficacy of Abacavir can be decreased when used in combination with Methadone.
AbirateroneThe serum concentration of Methadone can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Methadone.
AcepromazineAcepromazine may increase the hypotensive activities of Methadone.
AcepromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Methadone is combined with Aceprometazine.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Methadone.
AcetazolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Acetazolamide.
AcetophenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Acetophenazine.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Methadone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Methadone.
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Methadone.
adipiplonThe risk or severity of adverse effects can be increased when Methadone is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Methadone.
AgomelatineThe risk or severity of adverse effects can be increased when Methadone is combined with Agomelatine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Methadone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Methadone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Methadone is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Methadone.
AlimemazineAlimemazine may increase the hypotensive activities of Methadone.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Methadone.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Methadone.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Methadone.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Methadone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methadone is combined with Alphacetylmethadol.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
AlprazolamThe risk or severity of adverse effects can be increased when Methadone is combined with Alprazolam.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Methadone.
AlvimopanThe risk or severity of adverse effects can be increased when Methadone is combined with Alvimopan.
AmantadineAmantadine may increase the QTc-prolonging activities of Methadone.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Methadone.
AmilorideThe risk or severity of adverse effects can be increased when Methadone is combined with Amiloride.
AminoglutethimideThe serum concentration of Methadone can be increased when it is combined with Aminoglutethimide.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Methadone.
AmiodaroneMethadone may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Methadone can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Methadone is combined with Amisulpride.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Methadone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Methadone.
Ammonium chlorideAmmonium chloride may increase the excretion rate of Methadone which could result in a higher serum level.
AmobarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Amobarbital.
AmoxapineMethadone may increase the serotonergic activities of Amoxapine.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Methadone.
AmperozideThe risk or severity of adverse effects can be increased when Methadone is combined with Amperozide.
AmphetamineAmphetamine may increase the analgesic activities of Methadone.
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Methadone.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Methadone.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Methadone.
AnagrelideMethadone may increase the QTc-prolonging activities of Anagrelide.
AnastrozoleThe serum concentration of Methadone can be increased when it is combined with Anastrozole.
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Methadone.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Methadone.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Methadone.
ApomorphineApomorphine may increase the QTc-prolonging activities of Methadone.
AprepitantThe serum concentration of Methadone can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Methadone.
ArformoterolArformoterol may increase the QTc-prolonging activities of Methadone.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Methadone.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Methadone.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Methadone.
ArmodafinilThe metabolism of Methadone can be decreased when combined with Armodafinil.
Arsenic trioxideMethadone may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherMethadone may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Methadone can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Methadone is combined with Articaine.
AsenapineMethadone may increase the QTc-prolonging activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methadone.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Methadone.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Methadone.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Methadone.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Methadone.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Methadone.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Methadone.
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methadone.
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Methadone.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Methadone.
AzaperoneThe risk or severity of adverse effects can be increased when Methadone is combined with Azaperone.
AzelastineMethadone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methadone.
AzithromycinMethadone may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Methadone can be decreased when combined with Azithromycin.
AzosemideThe risk or severity of adverse effects can be increased when Methadone is combined with Azosemide.
BaclofenThe risk or severity of adverse effects can be increased when Methadone is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Barbital.
BedaquilineMethadone may increase the QTc-prolonging activities of Bedaquiline.
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Methadone.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Bendroflumethiazide.
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Methadone.
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Methadone.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Methadone.
BenzocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Benzocaine.
BenzphetamineBenzphetamine may increase the analgesic activities of Methadone.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Methadone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methadone.
BepridilThe metabolism of Bepridil can be decreased when combined with Methadone.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Methadone.
BetaxololThe metabolism of Methadone can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Methadone can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Methadone is combined with Bifeprunox.
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Methadone.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Methadone.
BoceprevirThe serum concentration of Methadone can be increased when it is combined with Boceprevir.
BortezomibBortezomib may increase the QTc-prolonging activities of Methadone.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Methadone.
BosentanThe serum concentration of Methadone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Methadone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Methadone.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Methadone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Methadone.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
BrimonidineThe risk or severity of adverse effects can be increased when Methadone is combined with Brimonidine.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
BromazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Methadone.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Methadone.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Methadone.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methadone.
BrotizolamThe risk or severity of adverse effects can be increased when Methadone is combined with Brotizolam.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Methadone.
BumetanideThe risk or severity of adverse effects can be increased when Methadone is combined with Bumetanide.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Methadone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methadone.
BuprenorphineBuprenorphine may decrease the analgesic activities of Methadone.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Methadone.
BupropionThe metabolism of Bupropion can be decreased when combined with Methadone.
BuserelinBuserelin may increase the QTc-prolonging activities of Methadone.
BuspironeThe metabolism of Buspirone can be decreased when combined with Methadone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methadone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methadone.
ButacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Methadone is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Methadone is combined with Butethal.
ButorphanolButorphanol may decrease the analgesic activities of Methadone.
ButorphanolThe risk or severity of adverse effects can be increased when Methadone is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Methadone.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Methadone.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Methadone.
CaffeineThe metabolism of Methadone can be decreased when combined with Caffeine.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Methadone.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Methadone.
Canrenoic acidThe risk or severity of adverse effects can be increased when Methadone is combined with Canrenoic acid.
CapecitabineThe metabolism of Methadone can be decreased when combined with Capecitabine.
CaptoprilThe metabolism of Captopril can be decreased when combined with Methadone.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Methadone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methadone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methadone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Methadone.
CariprazineThe risk or severity of adverse effects can be increased when Methadone is combined with Cariprazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Methadone is combined with Carisoprodol.
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Methadone.
CarteololThe metabolism of Carteolol can be decreased when combined with Methadone.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Methadone.
CelecoxibThe metabolism of Methadone can be decreased when combined with Celecoxib.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Methadone.
CeritinibThe serum concentration of Methadone can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Methadone.
CetirizineThe risk or severity of adverse effects can be increased when Methadone is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Methadone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Methadone is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Methadone can be decreased when combined with Chloramphenicol.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Methadone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Chloroprocaine.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Methadone.
ChlorothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Methadone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methadone.
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methadone.
ChlorphentermineChlorphentermine may increase the analgesic activities of Methadone.
ChlorpromazineChlorpromazine may increase the hypotensive activities of Methadone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorthalidone.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Methadone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methadone.
CholecalciferolThe metabolism of Methadone can be decreased when combined with Cholecalciferol.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Methadone.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Methadone.
CimetidineThe metabolism of Methadone can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Methadone can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Methadone.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Methadone.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Methadone.
CisaprideMethadone may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Methadone.
CitalopramMethadone may increase the QTc-prolonging activities of Citalopram.
CitalopramThe metabolism of Methadone can be decreased when combined with Citalopram.
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Methadone.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Methadone.
ClemastineThe metabolism of Methadone can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Methadone is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Methadone.
ClidiniumThe risk or severity of adverse effects can be increased when Methadone is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Methadone.
ClobazamThe metabolism of Methadone can be decreased when combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Methadone is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Methadone.
ClomipramineMethadone may increase the serotonergic activities of Clomipramine.
ClomipramineClomipramine may increase the QTc-prolonging activities of Methadone.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ClonazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Methadone.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methadone.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Methadone.
ClopidogrelThe metabolism of Methadone can be decreased when combined with Clopidogrel.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Methadone.
ClorazepateThe risk or severity of adverse effects can be increased when Methadone is combined with Clorazepate.
ClotrimazoleThe metabolism of Methadone can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Methadone is combined with Clozapine.
ClozapineThe metabolism of Methadone can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Methadone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Methadone.
CocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Methadone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methadone.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Methadone.
ConivaptanThe serum concentration of Methadone can be increased when it is combined with Conivaptan.
ConivaptanThe risk or severity of adverse effects can be increased when Methadone is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Methadone.
CrizotinibThe metabolism of Methadone can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Methadone.
CyamemazineThe risk or severity of adverse effects can be increased when Methadone is combined with Cyamemazine.
CyclizineThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclizine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Methadone.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methadone.
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methadone.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Methadone.
CyclosporineThe metabolism of Methadone can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Methadone.
CyclothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclothiazide.
CyproheptadineThe risk or severity of adverse effects can be increased when Methadone is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Methadone can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Methadone.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Methadone.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Methadone.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Methadone.
DantroleneThe risk or severity of adverse effects can be increased when Methadone is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Methadone.
DapiprazoleThe risk or severity of adverse effects can be increased when Methadone is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Methadone.
DapoxetineMethadone may increase the serotonergic activities of Dapoxetine.
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methadone.
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Methadone.
DarunavirThe serum concentration of Methadone can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Methadone.
DasatinibThe serum concentration of Methadone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Methadone.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Methadone.
DeferasiroxThe serum concentration of Methadone can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Methadone.
DelavirdineThe metabolism of Methadone can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Methadone is combined with deramciclane.
DesfluraneDesflurane may increase the QTc-prolonging activities of Methadone.
DesfluraneThe risk or severity of adverse effects can be increased when Methadone is combined with Desflurane.
DesipramineDesipramine may increase the QTc-prolonging activities of Methadone.
DesipramineThe metabolism of Desipramine can be decreased when combined with Methadone.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methadone.
DesmopressinThe risk or severity of adverse effects can be increased when Methadone is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methadone is combined with Desvenlafaxine.
DetomidineThe risk or severity of adverse effects can be increased when Methadone is combined with Detomidine.
DexamethasoneThe serum concentration of Methadone can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Methadone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methadone is combined with Dexbrompheniramine.
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Methadone.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Methadone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Methadone is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Methadone.
DextroamphetamineDextroamphetamine may increase the analgesic activities of Methadone.
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Methadone.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Methadone.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Methadone.
DextromoramideThe risk or severity of adverse effects can be increased when Methadone is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methadone is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Methadone is combined with Dezocine.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Methadone.
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methadone.
DidanosineThe serum concentration of Didanosine can be decreased when it is combined with Methadone.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Methadone.
DifenoxinThe risk or severity of adverse effects can be increased when Methadone is combined with Difenoxin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Methadone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Methadone.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Methadone.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methadone.
DihydroergotamineThe metabolism of Methadone can be decreased when combined with Dihydroergotamine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydroergotamine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Methadone is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Methadone.
DiltiazemThe metabolism of Methadone can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Methadone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methadone is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Methadone.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Methadone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Methadone is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Methadone.
DisopyramideMethadone may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Methadone.
DofetilideMethadone may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the serotonergic activities of Methadone.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Methadone.
DomperidoneMethadone may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Methadone.
DopamineThe metabolism of Dopamine can be decreased when combined with Methadone.
DoramectinThe risk or severity of adverse effects can be increased when Methadone is combined with Doramectin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Methadone.
DoxepinDoxepin may increase the QTc-prolonging activities of Methadone.
DoxepinThe metabolism of Doxepin can be decreased when combined with Methadone.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Methadone.
DoxorubicinThe metabolism of Methadone can be decreased when combined with Doxorubicin.
DoxycyclineThe metabolism of Methadone can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
DoxylamineThe risk or severity of adverse effects can be increased when Methadone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Methadone is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methadone.
DronedaroneMethadone may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Methadone can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Methadone is combined with Droperidol.
DrospirenoneThe risk or severity of adverse effects can be increased when Methadone is combined with Drospirenone.
DrotebanolThe risk or severity of adverse effects can be increased when Methadone is combined with Drotebanol.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Methadone.
DyclonineThe risk or severity of adverse effects can be increased when Methadone is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Methadone is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methadone is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Methadone.
EfavirenzThe serum concentration of Methadone can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Methadone is combined with Efavirenz.
EfonidipineThe risk or severity of adverse effects can be increased when Methadone is combined with Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Methadone.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Methadone.
EliglustatMethadone may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Methadone can be decreased when combined with Eliglustat.
EluxadolineMethadone may increase the constipating activities of Eluxadoline.
EncainideThe metabolism of Encainide can be decreased when combined with Methadone.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Methadone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methadone.
EntacaponeThe risk or severity of adverse effects can be increased when Methadone is combined with Entacapone.
EnzalutamideThe serum concentration of Methadone can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Methadone.
EplerenoneThe risk or severity of adverse effects can be increased when Methadone is combined with Eplerenone.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Methadone is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Methadone is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Methadone is combined with Ergotamine.
EribulinEribulin may increase the QTc-prolonging activities of Methadone.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Methadone.
ErythromycinThe metabolism of Methadone can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Methadone.
EscitalopramThe metabolism of Methadone can be decreased when combined with Escitalopram.
EscitalopramMethadone may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Methadone can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Methadone.
EsomeprazoleThe metabolism of Methadone can be decreased when combined with Esomeprazole.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
EstazolamThe risk or severity of adverse effects can be increased when Methadone is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Methadone.
EstriolThe serum concentration of Estriol can be increased when it is combined with Methadone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Methadone.
EszopicloneThe risk or severity of adverse effects can be increased when Methadone is combined with Eszopiclone.
Etacrynic acidThe risk or severity of adverse effects can be increased when Methadone is combined with Etacrynic acid.
EthanolMethadone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methadone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Methadone.
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Methadone.
EthosuximideThe risk or severity of adverse effects can be increased when Methadone is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methadone is combined with Ethotoin.
EthoxzolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Ethoxzolamide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methadone is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methadone is combined with Ethyl loflazepate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Methadone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methadone.
EtidocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Methadone is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Methadone is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadone.
EtoperidoneThe metabolism of Methadone can be decreased when combined with Etoperidone.
EtoperidoneMethadone may increase the serotonergic activities of Etoperidone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Methadone.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Methadone.
EtorphineThe risk or severity of adverse effects can be increased when Methadone is combined with Etorphine.
EtravirineThe serum concentration of Methadone can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Methadone.
ExemestaneThe serum concentration of Methadone can be increased when it is combined with Exemestane.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Methadone.
EzogabineEzogabine may increase the QTc-prolonging activities of Methadone.
EzogabineThe risk or severity of adverse effects can be increased when Methadone is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Methadone.
FelbamateFelbamate may increase the QTc-prolonging activities of Methadone.
FelbamateThe risk or severity of adverse effects can be increased when Methadone is combined with Felbamate.
FelodipineThe metabolism of Methadone can be decreased when combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Methadone is combined with Fencamfamine.
FenfluramineThe metabolism of Methadone can be decreased when combined with Fenfluramine.
FenfluramineMethadone may increase the serotonergic activities of Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Methadone is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methadone.
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Methadone.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Methadone.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Methadone.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Methadone.
FingolimodFingolimod may increase the QTc-prolonging activities of Methadone.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Methadone.
FlecainideFlecainide may increase the QTc-prolonging activities of Methadone.
FlecainideThe metabolism of Flecainide can be decreased when combined with Methadone.
FlibanserinThe risk or severity of adverse effects can be increased when Methadone is combined with Flibanserin.
FloxuridineThe metabolism of Methadone can be decreased when combined with Floxuridine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Methadone.
FludiazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Fludiazepam.
FlumazenilFlumazenil may increase the central nervous system depressant (CNS depressant) activities of Methadone.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Methadone.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methadone.
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
FlunitrazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Flunitrazepam.
FluorouracilThe metabolism of Methadone can be decreased when combined with Fluorouracil.
FluoxetineMethadone may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe metabolism of Methadone can be decreased when combined with Fluoxetine.
FlupentixolMethadone may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methadone.
FluphenazineFluphenazine may increase the hypotensive activities of Methadone.
FluphenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Fluphenazine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
FlurazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Methadone is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Methadone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methadone is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Methadone.
FluvoxamineMethadone may increase the serotonergic activities of Fluvoxamine.
FluvoxamineThe metabolism of Methadone can be decreased when combined with Fluvoxamine.
FormestaneThe serum concentration of Methadone can be increased when it is combined with Formestane.
FormoterolFormoterol may increase the QTc-prolonging activities of Methadone.
FormoterolThe metabolism of Formoterol can be decreased when combined with Methadone.
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Methadone resulting in a loss in efficacy.
FosamprenavirThe metabolism of Methadone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Methadone can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Methadone.
FosphenytoinThe serum concentration of Methadone can be decreased when it is combined with Fosphenytoin.
FosphenytoinThe risk or severity of adverse effects can be increased when Methadone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Methadone is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Frovatriptan.
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Methadone.
FurosemideThe risk or severity of adverse effects can be increased when Methadone is combined with Furosemide.
Fusidic AcidThe serum concentration of Methadone can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Methadone is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methadone is combined with gabapentin enacarbil.
Gadobenic acidMethadone may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Methadone.
GalantamineThe metabolism of Galantamine can be decreased when combined with Methadone.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Methadone.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methadone is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Methadone.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Methadone.
GemfibrozilThe metabolism of Methadone can be decreased when combined with Gemfibrozil.
GemifloxacinMethadone may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideThe risk or severity of adverse effects can be increased when Methadone is combined with Glutethimide.
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Methadone.
GoserelinGoserelin may increase the QTc-prolonging activities of Methadone.
GranisetronGranisetron may increase the serotonergic activities of Methadone.
GranisetronThe metabolism of Granisetron can be decreased when combined with Methadone.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Methadone.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Methadone.
GuanfacineThe risk or severity of adverse effects can be increased when Methadone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Methadone.
HaloperidolThe risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.
HaloperidolThe metabolism of Methadone can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Methadone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methadone.
HeroinThe risk or severity of adverse effects can be increased when Methadone is combined with Heroin.
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Methadone.
HexobarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Methadone.
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Methadone.
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Methadone.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Hydrochlorothiazide.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Methadone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methadone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Methadone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Hydroflumethiazide.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Methadone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methadone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Methadone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
HydroxyzineThe risk or severity of adverse effects can be increased when Methadone is combined with Hydroxyzine.
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methadone.
IbandronateIbandronate may increase the QTc-prolonging activities of Methadone.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Methadone.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Methadone.
IbutilideMethadone may increase the QTc-prolonging activities of Ibutilide.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Methadone.
IdelalisibThe serum concentration of Methadone can be increased when it is combined with Idelalisib.
IloperidoneMethadone may increase the QTc-prolonging activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methadone.
ImatinibThe metabolism of Methadone can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Methadone.
ImipramineImipramine may increase the QTc-prolonging activities of Methadone.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Methadone.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Methadone.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Methadone.
IndalpineThe metabolism of Methadone can be decreased when combined with Indalpine.
IndalpineMethadone may increase the serotonergic activities of Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Methadone is combined with Indapamide.
IndapamideIndapamide may increase the QTc-prolonging activities of Methadone.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Methadone.
IndinavirThe metabolism of Methadone can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Methadone.
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methadone.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Methadone.
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Methadone.
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Methadone.
IrbesartanThe metabolism of Methadone can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Methadone.
IsavuconazoniumThe metabolism of Methadone can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Methadone.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Methadone.
IsofluraneThe risk or severity of adverse effects can be increased when Methadone is combined with Isoflurane.
IsoniazidThe metabolism of Methadone can be decreased when combined with Isoniazid.
IsosorbideThe risk or severity of adverse effects can be increased when Methadone is combined with Isosorbide.
IsradipineIsradipine may increase the QTc-prolonging activities of Methadone.
ItraconazoleThe serum concentration of Methadone can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Methadone.
IvacaftorThe serum concentration of Methadone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Methadone.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Methadone.
KetamineThe risk or severity of adverse effects can be increased when Methadone is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Methadone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methadone.
KetobemidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ketobemidone.
KetoconazoleThe serum concentration of Methadone can be increased when it is combined with Ketoconazole.
KW-3902The risk or severity of adverse effects can be increased when Methadone is combined with KW-3902.
LabetalolThe metabolism of Labetalol can be decreased when combined with Methadone.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Methadone.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Methadone.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methadone.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Methadone.
LapatinibLapatinib may increase the QTc-prolonging activities of Methadone.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Methadone.
LeflunomideThe metabolism of Methadone can be decreased when combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Methadone.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Methadone.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Methadone.
LetrozoleThe serum concentration of Methadone can be increased when it is combined with Letrozole.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Methadone.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Methadone.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methadone.
LevobupivacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Methadone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methadone is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Methadone.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Methadone.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Methadone.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Methadone.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methadone is combined with Levomethadyl Acetate.
LevomilnacipranThe metabolism of Methadone can be decreased when combined with Levomilnacipran.
LevomilnacipranMethadone may increase the serotonergic activities of Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Methadone is combined with Levorphanol.
LidocaineThe metabolism of Methadone can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Methadone.
LinezolidThe risk or severity of adverse effects can be increased when Methadone is combined with Linezolid.
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Methadone.
LisurideThe metabolism of Lisuride can be decreased when combined with Methadone.
LithiumThe risk or severity of adverse effects can be increased when Methadone is combined with Lithium.
LithiumLithium may increase the QTc-prolonging activities of Methadone.
LofentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Lofentanil.
LomustineThe metabolism of Lomustine can be decreased when combined with Methadone.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Methadone.
LopinavirMethadone may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe metabolism of Methadone can be decreased when combined with Lopinavir.
LoratadineThe metabolism of Loratadine can be decreased when combined with Methadone.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Methadone.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
LorazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Lorazepam.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Methadone.
LosartanThe serum concentration of Losartan can be increased when it is combined with Methadone.
LosartanThe metabolism of Methadone can be decreased when combined with Losartan.
LovastatinThe metabolism of Methadone can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Methadone is combined with Loxapine.
Lu AA21004Methadone may increase the serotonergic activities of Lu AA21004.
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Methadone.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Methadone.
LuliconazoleThe serum concentration of Methadone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Methadone can be decreased when it is combined with Lumacaftor.
LumefantrineMethadone may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Methadone can be decreased when combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Methadone is combined with Magnesium Sulfate.
MannitolThe risk or severity of adverse effects can be increased when Methadone is combined with Mannitol.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Methadone.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Methadone.
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Methadone.
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methadone.
MeclizineThe risk or severity of adverse effects can be increased when Methadone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Methadone is combined with Medetomidine.
MefloquineMefloquine may increase the QTc-prolonging activities of Methadone.
MelatoninThe risk or severity of adverse effects can be increased when Methadone is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Methadone is combined with Melperone.
MephentermineMephentermine may increase the analgesic activities of Methadone.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Methadone.
MepivacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Methadone is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Methadone.
MersalylThe risk or severity of adverse effects can be increased when Methadone is combined with Mersalyl.
MesoridazineMesoridazine may increase the hypotensive activities of Methadone.
MesoridazineThe risk or severity of adverse effects can be increased when Methadone is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Methadone is combined with Metaxalone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadone is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may increase the analgesic activities of Methadone.
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Methadone.
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Methadone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methadone is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methaqualone.
MethazolamideThe risk or severity of adverse effects can be increased when Methadone is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methadone is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methadone is combined with Methohexital.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Methadone.
MethotrimeprazineMethotrimeprazine may increase the hypotensive activities of Methadone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methadone is combined with Methotrimeprazine.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Methadone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methadone.
MethsuximideThe risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Methyclothiazide.
Methylene blueMethylene blue may increase the hypotensive activities of Methadone.
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Methadone.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Methadone.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Methadone.
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Methadone.
MetoclopramideThe risk or severity of adverse effects can be increased when Methadone is combined with Metoclopramide.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Methadone.
MetolazoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metolazone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Methadone.
MetoprololThe metabolism of Methadone can be decreased when combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Methadone.
MetyrosineMethadone may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Methadone can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Methadone.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Methadone.
MifepristoneMifepristone may increase the QTc-prolonging activities of Methadone.
MilnacipranThe metabolism of Methadone can be decreased when combined with Milnacipran.
MilnacipranMethadone may increase the serotonergic activities of Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Methadone.
MinaprineThe metabolism of Minaprine can be decreased when combined with Methadone.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methadone.
MirabegronMirabegron may increase the QTc-prolonging activities of Methadone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Methadone.
MirtazapineMethadone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Methadone.
MitotaneThe serum concentration of Methadone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Methadone.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Methadone.
ModafinilThe serum concentration of Methadone can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Methadone.
MolindoneThe risk or severity of adverse effects can be increased when Methadone is combined with Molindone.
MoricizineMoricizine may increase the hypotensive activities of Methadone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Methadone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methadone.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Methadone.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Methadone.
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Methadone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadone.
NabiloneThe risk or severity of adverse effects can be increased when Methadone is combined with Nabilone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Methadone.
NafcillinThe serum concentration of Methadone can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may decrease the analgesic activities of Methadone.
NalbuphineThe risk or severity of adverse effects can be increased when Methadone is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Methadone.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Methadone.
NaltrexoneThe therapeutic efficacy of Methadone can be decreased when used in combination with Naltrexone.
NaratriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Naratriptan.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Methadone.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Methadone.
NefazodoneThe metabolism of Methadone can be decreased when combined with Nefazodone.
NelfinavirThe serum concentration of Methadone can be decreased when it is combined with Nelfinavir.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Methadone.
NetupitantThe serum concentration of Methadone can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Methadone.
NevirapineThe metabolism of Methadone can be decreased when combined with Nevirapine.
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Methadone.
NicardipineNicardipine may increase the QTc-prolonging activities of Methadone.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Methadone.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Methadone.
NicotineThe metabolism of Nicotine can be decreased when combined with Methadone.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Methadone.
NilotinibMethadone may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Methadone can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Methadone.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
NitrazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Nitrazepam.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Methadone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Methadone is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Methadone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Methadone.
NormethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Normethadone.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Methadone.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Methadone.
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Methadone.
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Methadone.
OctreotideOctreotide may increase the QTc-prolonging activities of Methadone.
OfloxacinMethadone may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineMethadone may increase the serotonergic activities of Olanzapine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Methadone.
OlaparibThe metabolism of Methadone can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Methadone.
OlopatadineThe risk or severity of adverse effects can be increased when Methadone is combined with Olopatadine.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Methadone.
OmeprazoleThe metabolism of Methadone can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Methadone is combined with Ondansetron.
OndansetronOndansetron may increase the serotonergic activities of Methadone.
OpiumThe risk or severity of adverse effects can be increased when Methadone is combined with Opium.
OrphenadrineMethadone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methadone.
OsanetantThe risk or severity of adverse effects can be increased when Methadone is combined with Osanetant.
OsimertinibThe serum concentration of Methadone can be increased when it is combined with Osimertinib.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
OxazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Methadone is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Oxybuprocaine.
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methadone.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Methadone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methadone.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Methadone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methadone.
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Methadone.
OxytocinOxytocin may increase the QTc-prolonging activities of Methadone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Methadone.
PalbociclibThe serum concentration of Methadone can be increased when it is combined with Palbociclib.
PaliperidoneMethadone may increase the QTc-prolonging activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methadone.
PalonosetronPalonosetron may increase the serotonergic activities of Methadone.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Methadone.
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methadone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Methadone.
PanobinostatThe metabolism of Methadone can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Methadone can be decreased when combined with Pantoprazole.
ParaldehydeMethadone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methadone.
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Methadone.
ParoxetineMethadone may increase the serotonergic activities of Paroxetine.
ParoxetineParoxetine may increase the QTc-prolonging activities of Methadone.
PasireotidePasireotide may increase the QTc-prolonging activities of Methadone.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Methadone.
PazopanibPazopanib may increase the QTc-prolonging activities of Methadone.
Peginterferon alfa-2bThe serum concentration of Methadone can be decreased when it is combined with Peginterferon alfa-2b.
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methadone.
PentamidinePentamidine may increase the QTc-prolonging activities of Methadone.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Methadone.
PentazocinePentazocine may decrease the analgesic activities of Methadone.
PentazocineThe risk or severity of adverse effects can be increased when Methadone is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methadone.
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Methadone.
PerampanelThe risk or severity of adverse effects can be increased when Methadone is combined with Perampanel.
PerflutrenMethadone may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Methadone.
PerospironeThe risk or severity of adverse effects can be increased when Methadone is combined with Perospirone.
PerphenazinePerphenazine may increase the hypotensive activities of Methadone.
PerphenazineThe risk or severity of adverse effects can be increased when Methadone is combined with Perphenazine.
PethidineThe metabolism of Pethidine can be decreased when combined with Methadone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methadone.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Methadone.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Methadone.
PhenforminThe metabolism of Phenformin can be decreased when combined with Methadone.
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Methadone.
PhenobarbitalThe serum concentration of Methadone can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Methadone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methadone is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Methadone.
PhenterminePhentermine may increase the analgesic activities of Methadone.
PhenytoinThe serum concentration of Methadone can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Methadone.
PimozideMethadone may increase the QTc-prolonging activities of Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methadone.
PindololThe metabolism of Pindolol can be decreased when combined with Methadone.
PioglitazoneThe metabolism of Methadone can be decreased when combined with Pioglitazone.
PipamperoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pipamperone.
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methadone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Methadone.
PipotiazineThe risk or severity of adverse effects can be increased when Methadone is combined with Pipotiazine.
PirenzepinePirenzepine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
PiretanideThe risk or severity of adverse effects can be increased when Methadone is combined with Piretanide.
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Methadone.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Methadone.
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Methadone.
PizotifenThe risk or severity of adverse effects can be increased when Methadone is combined with Pizotifen.
PolythiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Methadone.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methadone.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Methadone.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Methadone.
PotassiumThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium.
Potassium CitrateThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium Citrate.
PramipexoleMethadone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Methadone.
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
PrazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Prazepam.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Methadone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Methadone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Methadone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methadone.
PrilocaineThe risk or severity of adverse effects can be increased when Methadone is combined with Prilocaine.
PrimaquineMethadone may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe serum concentration of Methadone can be decreased when it is combined with Primidone.
PrimidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Primidone.
ProcainamideMethadone may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Methadone is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Methadone is combined with Procarbazine.
ProchlorperazineProchlorperazine may increase the hypotensive activities of Methadone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Methadone is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methadone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Methadone.
PromazinePromazine may increase the hypotensive activities of Methadone.
PromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Promazine.
PromethazinePromethazine may increase the hypotensive activities of Methadone.
PromethazineThe metabolism of Promethazine can be decreased when combined with Methadone.
PropafenoneThe serum concentration of Methadone can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Methadone.
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Methadone.
ProparacaineThe risk or severity of adverse effects can be increased when Methadone is combined with Proparacaine.
PropericiazineThe risk or severity of adverse effects can be increased when Methadone is combined with Propericiazine.
PropofolPropofol may increase the QTc-prolonging activities of Methadone.
PropofolThe metabolism of Propofol can be decreased when combined with Methadone.
PropoxycaineThe risk or severity of adverse effects can be increased when Methadone is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Methadone.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Methadone.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Methadone.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Methadone.
PSD502The risk or severity of adverse effects can be increased when Methadone is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Methadone.
PyrimethamineThe metabolism of Methadone can be decreased when combined with Pyrimethamine.
QuazepamThe serum concentration of Methadone can be increased when it is combined with Quazepam.
QuazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Quazepam.
QuetiapineMethadone may increase the QTc-prolonging activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methadone.
QuinethazoneThe risk or severity of adverse effects can be increased when Methadone is combined with Quinethazone.
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Methadone.
QuinidineMethadone may increase the QTc-prolonging activities of Quinidine.
QuinineMethadone may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Methadone can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Methadone can be decreased when combined with Rabeprazole.
RamelteonThe risk or severity of adverse effects can be increased when Methadone is combined with Ramelteon.
RamosetronMethadone may increase the constipating activities of Ramosetron.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Methadone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Methadone.
RanolazineRanolazine may increase the QTc-prolonging activities of Methadone.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Methadone.
RemifentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Methadone is combined with Remoxipride.
repinotanThe metabolism of repinotan can be decreased when combined with Methadone.
ReserpineThe risk or severity of adverse effects can be increased when Methadone is combined with Reserpine.
RifabutinThe metabolism of Methadone can be increased when combined with Rifabutin.
RifampicinThe metabolism of Methadone can be increased when combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Methadone.
RifapentineThe metabolism of Methadone can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Methadone.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Methadone.
RisperidoneThe risk or severity of adverse effects can be increased when Methadone is combined with Risperidone.
RisperidoneRisperidone may increase the QTc-prolonging activities of Methadone.
RitonavirThe serum concentration of Methadone can be decreased when it is combined with Ritonavir.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Methadone.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Methadone.
RizatriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Rizatriptan.
RolapitantThe metabolism of Methadone can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Methadone.
RomifidineThe risk or severity of adverse effects can be increased when Methadone is combined with Romifidine.
RopiniroleMethadone may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Methadone can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Methadone.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methadone.
RosiglitazoneThe metabolism of Methadone can be decreased when combined with Rosiglitazone.
RotigotineMethadone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methadone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methadone is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Methadone.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Methadone.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Methadone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Methadone.
SaquinavirSaquinavir may increase the QTc-prolonging activities of Methadone.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Methadone.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Methadone.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methadone.
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methadone.
SecobarbitalThe risk or severity of adverse effects can be increased when Methadone is combined with Secobarbital.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Methadone.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Methadone.
SertindoleThe risk or severity of adverse effects can be increased when Methadone is combined with Sertindole.
SertralineMethadone may increase the serotonergic activities of Sertraline.
SertralineSertraline may increase the QTc-prolonging activities of Methadone.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Methadone.
SevofluraneThe risk or severity of adverse effects can be increased when Methadone is combined with Sevoflurane.
SildenafilThe metabolism of Methadone can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Methadone.
SiltuximabThe serum concentration of Methadone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Methadone can be increased when it is combined with Simeprevir.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Methadone.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Methadone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Methadone is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Methadone.
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Methadone.
SorafenibSorafenib may increase the QTc-prolonging activities of Methadone.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Methadone.
SotalolMethadone may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Methadone.
SparteineThe metabolism of Sparteine can be decreased when combined with Methadone.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Methadone.
SpironolactoneThe risk or severity of adverse effects can be increased when Methadone is combined with Spironolactone.
St. John's WortThe serum concentration of Methadone can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Methadone is combined with Stiripentol.
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Methadone.
SufentanilThe risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.
SulfadiazineThe metabolism of Methadone can be decreased when combined with Sulfadiazine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Methadone.
SulfisoxazoleMethadone may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Methadone can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Methadone is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Methadone is combined with Sumatriptan.
SunitinibSunitinib may increase the QTc-prolonging activities of Methadone.
SuvorexantThe risk or severity of adverse effects can be increased when Methadone is combined with Suvorexant.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Methadone.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Methadone.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Methadone.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Methadone.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Methadone.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Methadone.
TasimelteonThe risk or severity of adverse effects can be increased when Methadone is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Methadone.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Methadone.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Methadone.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Methadone is combined with Tedizolid Phosphate.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Methadone.
TelaprevirThe serum concentration of Methadone can be decreased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Methadone.
TelavancinMethadone may increase the QTc-prolonging activities of Telavancin.
TelithromycinMethadone may increase the QTc-prolonging activities of Telithromycin.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
TemazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Temazepam.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Methadone.
TenofovirThe metabolism of Methadone can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Methadone can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Methadone.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Methadone.
TeriflunomideThe serum concentration of Methadone can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Methadone.
TetrabenazineMethadone may increase the QTc-prolonging activities of Tetrabenazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methadone.
TetracaineThe risk or severity of adverse effects can be increased when Methadone is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Methadone is combined with Tetrodotoxin.
ThalidomideMethadone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methadone.
TheobromineThe risk or severity of adverse effects can be increased when Methadone is combined with Theobromine.
TheophyllineThe metabolism of Methadone can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Methadone is combined with Thiamylal.
ThiethylperazineThiethylperazine may increase the hypotensive activities of Methadone.
ThiopentalThe risk or severity of adverse effects can be increased when Methadone is combined with Thiopental.
ThioproperazineThe risk or severity of adverse effects can be increased when Methadone is combined with Thioproperazine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Methadone.
ThioridazineThioridazine may increase the hypotensive activities of Methadone.
ThiotepaThe metabolism of Methadone can be decreased when combined with Thiotepa.
ThiothixeneThe risk or severity of adverse effects can be increased when Methadone is combined with Thiothixene.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Methadone.
TiagabineThe risk or severity of adverse effects can be increased when Methadone is combined with Tiagabine.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Methadone.
TicagrelorThe metabolism of Methadone can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Methadone can be decreased when combined with Ticlopidine.
TicrynafenThe risk or severity of adverse effects can be increased when Methadone is combined with Ticrynafen.
TiletamineThe risk or severity of adverse effects can be increased when Methadone is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Methadone.
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Methadone.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Methadone.
TipranavirThe serum concentration of Methadone can be decreased when it is combined with Tipranavir.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Methadone.
TizanidineTizanidine may increase the QTc-prolonging activities of Methadone.
TizanidineThe risk or severity of adverse effects can be increased when Methadone is combined with Tizanidine.
TocilizumabThe serum concentration of Methadone can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Methadone can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Methadone is combined with Tolcapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Methadone.
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Methadone.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Methadone.
TolvaptanThe risk or severity of adverse effects can be increased when Methadone is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Methadone is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Methadone.
TorasemideThe risk or severity of adverse effects can be increased when Methadone is combined with Torasemide.
ToremifeneMethadone may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Methadone.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Methadone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methadone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methadone is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe metabolism of Methadone can be decreased when combined with Tranylcypromine.
TranylcypromineThe risk or severity of adverse effects can be increased when Methadone is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Methadone.
TrazodoneMethadone may increase the serotonergic activities of Trazodone.
TrazodoneTrazodone may increase the QTc-prolonging activities of Methadone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Methadone.
TriamtereneThe risk or severity of adverse effects can be increased when Methadone is combined with Triamterene.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Methadone.
TriazolamThe risk or severity of adverse effects can be increased when Methadone is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Methadone is combined with Trichlormethiazide.
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Methadone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Methadone is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the hypotensive activities of Methadone.
TriflupromazineThe risk or severity of adverse effects can be increased when Methadone is combined with Triflupromazine.
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methadone.
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Methadone.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Methadone.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Methadone.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Methadone.
TriprolidineThe risk or severity of adverse effects can be increased when Methadone is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Methadone.
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methadone.
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Methadone.
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methadone.
UlaritideThe risk or severity of adverse effects can be increased when Methadone is combined with Ularitide.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Methadone.
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Methadone.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Methadone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methadone.
ValsartanThe metabolism of Methadone can be decreased when combined with Valsartan.
VandetanibMethadone may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Methadone.
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methadone.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Methadone.
VemurafenibThe serum concentration of Methadone can be increased when it is combined with Vemurafenib.
VemurafenibMethadone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Methadone.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Methadone.
VerapamilThe metabolism of Methadone can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Methadone.
VigabatrinThe risk or severity of adverse effects can be increased when Methadone is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Methadone.
VilazodoneThe metabolism of Methadone can be decreased when combined with Vilazodone.
VilazodoneMethadone may increase the serotonergic activities of Vilazodone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Methadone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Methadone.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Methadone.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Methadone.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Methadone.
VorinostatVorinostat may increase the QTc-prolonging activities of Methadone.
VortioxetineMethadone may increase the serotonergic activities of Vortioxetine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Methadone.
XylazineThe risk or severity of adverse effects can be increased when Methadone is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Methadone.
ZafirlukastThe metabolism of Methadone can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Methadone.
ZaleplonThe risk or severity of adverse effects can be increased when Methadone is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Methadone is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Methadone.
ZimelidineThe metabolism of Methadone can be decreased when combined with Zimelidine.
ZimelidineMethadone may increase the serotonergic activities of Zimelidine.
ZiprasidoneMethadone may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Methadone can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Methadone is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Methadone.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Methadone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methadone.
ZonisamideThe risk or severity of adverse effects can be increased when Methadone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Methadone is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Methadone is combined with Zotepine.
ZuclopenthixolMethadone may increase the QTc-prolonging activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methadone.
Food Interactions
  • Take without regard to meals. Avoid alcohol. Usually diluted in fruit juice.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60. [PubMed:11933204 ]
  4. Kakko J, von Wachenfeldt J, Svanborg KD, Lidstrom J, Barr CS, Heilig M: Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry. 2008 Jan 15;63(2):172-7. Epub 2007 Sep 11. [PubMed:17850768 ]
  5. Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F: Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med (Berl). 2004 Apr;82(4):250-5. Epub 2004 Jan 9. [PubMed:14991152 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein phosphatase 2a binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May play a role in the development of dendritic spines. May play a role in PPP2CB-NMDAR mediated signaling mechanism (By similarity).
Gene Name:
GRIN3A
Uniprot ID:
Q8TCU5
Molecular Weight:
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009 Oct;60(4):284-90. doi: 10.1016/j.phrs.2009.04.002. Epub 2009 Apr 11. [PubMed:19717013 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor binding
Specific Function:
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes t...
Gene Name:
CHRNA10
Uniprot ID:
Q9GZZ6
Molecular Weight:
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Gross ER, Hsu AK, Gross GJ: Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009 Nov;109(5):1395-402. doi: 10.1213/ANE.0b013e3181b92201. [PubMed:19843777 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Deeb TZ, Sharp D, Hales TG: Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol Pharmacol. 2009 Apr;75(4):908-17. doi: 10.1124/mol.108.053322. Epub 2009 Jan 8. [PubMed:19131665 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name:
CYP19A1
Uniprot ID:
P11511
Molecular Weight:
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ: Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6. [PubMed:11408360 ]
  2. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23